The FDA approves a new obesity pill, giving patients another option The FDA approves a new obesity pill, giving patients another option The Food and Drug Administration has approved the second GLP-1 pill to treat obesity, this time from drugmaker Eli Lilly
Once considered to act primarily through reductions in albuminuria, GLP-1RAs now have dedicated hard-endpoint evidence: in the FLOW trial, semaglutide reduced the primary composite kidney outcome ( 50% eGFR decline, kidney failure, or kidney or cardiovascular death) by 24% (hazard ratio 0.76, 95% CI 0.660.88) in type 2 diabetes and CKD and slowed eGFR decline [48, 49]
GLP-1 Weightloss Oct 6, 2025 2 min read If youve been searching for a safe, effective, and sustainable way to lose weight, Tirzepatide might be your breakthrough
T.PamerE
Ndulos Tiroideos: Diagnstico y Tratamiento Diagnstico y Tratamiento El diagnstico de los trastornos tiroideos generalmente involucra anlisis de sangre para medir los niveles de TSH, T3 y T4
The blend leverages the stability characteristics of each component peptide, with BPC-157s resistance to gastric acid degradation, TB-500s actin-binding properties, and GHK-Cus copper-mediated enzymatic activities working in concert to promote tissue healing across multiple pathways